We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
- Authors
Thalmann, G N; Sikes, R A; Chang, S M; Johnston, D A; von Eschenbach, A C; Chung, L W
- Abstract
Suramin, a polysulfonated naphthylurea and a recognized antitrypanosomal agent, has shown some promise in phase II clinical trials in the management of hormone-refractory human prostate cancer. Reduction of serum prostate-specific antigen (PSA) levels has been proposed as an end point for evaluating the antitumor efficacy of treatments for hormone-refractory prostate cancer.
- Publication
Journal of the National Cancer Institute, 1996, Vol 88, Issue 12, p794
- ISSN
0027-8874
- Publication type
Journal Article
- DOI
10.1093/jnci/88.12.794